Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06162572 · ClinicalTrials.gov registry record · Phase 1

Phase 1b/2 Platform Study of Select Immunotherapy Combinations in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)

A Phase 1 study of Non-small Cell Lung Cancer (NSCLC), sponsored by Servier Bio-Innovation.

Active
Registry status
Phase 1
Development phase
100
Enrollment target
20
Study locations

NCT06162572: Active Phase 1 study of Non-small Cell Lung Cancer (NSCLC), sponsored by Servier Bio-Innovation.

NCT06162572 is a Phase 1 study of Non-small Cell Lung Cancer (NSCLC) that is active but no longer recruiting, run by Servier Bio-Innovation. The registered enrollment target is 100 participants, below the 283-participant average among 59 other Non-small Cell Lung Cancer (NSCLC) trials with a reported enrollment target (65% lower). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06162572, a Phase 1 study of Non-small Cell Lung Cancer (NSCLC), is active but no longer recruiting, sponsored by Servier Bio-Innovation.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
100 participants
Enrollment target
20
Study locations

Study Summary

This is a Phase 1b/2 study evaluating the anti-PD1 antibody, cemiplimab, in combination with either S095018 (anti-TIM3 antibody), S095024 (anti-CD73 antibody), or S095029 (anti-NKG2A antibody) in adult participants with previously untreated advanced/metastatic non-small cell lung cancer (NSCLC) with high PD-L1 expression. The study includes two parts: part A, the combination-therapy safety lead-in phase to determine the recommended dose for expansion (RDE) for S095018, S095024, and S095029 in combination with cemiplimab and part B, the randomized dose expansion phase to assess the efficacy of S095018, S095024, or S095029 in combination with cemiplimab. Study treatment will be administered for a maximum of 108 weeks, or until confirmed disease progression per iRECIST and/ or until meeting other treatment discontinuation criteria.

Primary Outcome

Part A

Conditions Studied

Non-small Cell Lung Cancer (NSCLC)

Interventions

  • DRUG S095018
  • DRUG S095024
  • DRUG S095029
  • DRUG S095018 Recommended Dose Expansion (RDE)
  • DRUG S095024 RDE

Study Locations (20)

Other

  • Instituto Médico Especializado Alexander Fleming - Buenos Aires
  • Sanatorio Parque S.A. - Santa Fe
  • Border Medical Oncology Research Unit - Albury
  • Flinders Medical Centre - Bedford Park
  • Sunshine Hospital - St Albans
  • Latrobe Regional Health - Traralgon
  • Ordensklinikum Linz Elisabethinen - Linz
  • Universitatsklinikum St. Poelten - Sankt Pölten
  • Medical University of Vienna - Akh - Vienna
  • Jessa Ziekenhuis - Hasselt
  • Uz Leuven Campus Gasthuisberg - Leuven
  • Hospital de Amor - Barretos - Barretos
  • Supera Oncologia - Chapecó
  • CIONC - Curitiba

Ohio

  • Gabrail Cancer Center - Canton
  • Ohio State University Comprehensive Cancer Center - Columbus

California

  • Loma Linda University - Loma Linda

Michigan

  • Henry Ford Health - Detroit

Nevada

  • Comprehensive Cancer Center of Nevada - Las Vegas

Virginia

  • Virginia Cancer Specialists, P.C. - Fairfax

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2024-08-07
Est. Completion 2027-07
Phase Phase 1
Servier Bio-Innovation

9 total trials

What the registry record for NCT06162572 still lists

NCT06162572 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 283-participant average among 59 other Non-small Cell Lung Cancer (NSCLC) trials with a reported enrollment target (65% lower).

The record links to 1 condition, with Non-small Cell Lung Cancer (NSCLC) appearing as the primary indexed condition, and to 5 interventions - of which S095018 is the first listed.

NCT06162572 names 20 study sites across 6 states, led by Other, Ohio, California.

Frequently Asked Questions

What is clinical trial NCT06162572 about?

NCT06162572 is a clinical study titled "Phase 1b/2 Platform Study of Select Immunotherapy Combinations in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)". This is a Phase 1b/2 study evaluating the anti-PD1 antibody, cemiplimab, in combination with either S095018 (anti-TIM3 antibody), S095024 (anti-CD73 antibody), or S095029 (anti-NKG2A antibody) in adult participants with previously untreated advanced/metastatic non-small cell lung cancer (NSCLC) with...

What is the current status of trial NCT06162572?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 100 participants. The study started on 2024-08-07. Estimated completion is 2027-07.

What conditions does trial NCT06162572 study?

This clinical trial studies the following conditions: Non-small Cell Lung Cancer (NSCLC).

What interventions are being tested in trial NCT06162572?

The interventions under investigation include: S095018 (DRUG), S095024 (DRUG), S095029 (DRUG), S095018 Recommended Dose Expansion (RDE) (DRUG), S095024 RDE (DRUG).

Who is sponsoring clinical trial NCT06162572?

This trial is sponsored by Servier Bio-Innovation, which has 9 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06162572 being conducted?

This trial has 20 study locations across California, Michigan, Nevada, Ohio, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Non-small Cell Lung Cancer (NSCLC)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06162572's enrollment target sits among peer trials

100 36th of 59 higher than 23 of 59 other Non-small Cell Lung Cancer (NSCLC) trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Non-small Cell Lung Cancer (NSCLC) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01048281 · 100 participants

    Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma

  • NCT01161199 · 100 participants

    The Use of Leukapheresis to Support HIV Pathogenesis Studies

  • NCT01327690 · 100 participants · Early Phase 1

    Mental Health in Veterans and Families After Group Therapies

  • NCT01730781 · 100 participants

    Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT06162572, the US trial registry maintained by the National Library of Medicine. NCT06162572 (mid enrollment · wide site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.